Drug Trial Radar · NCT07055321
A Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of ETH47 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Jul 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Nov 29, 2023
Primary completion
Jul 8, 2024
Study completion Jul 8, 2024
Sponsor
- Lead sponsor
- Ethris GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jul 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics and target engagement of ETH47 in healthy participants following single intranasal and single inhaled administration
Conditions
- Healthy Subjects
Interventions
ETH47Drug
Dose level 1; single intranasal administration
ETH47Drug
Dose level 2; single intranasal administration
ETH47Drug
Dose level 3; single intranasal administration
ETH47Drug
Dose level 4; single intranasal administration
ETH47Drug
Dose level 5; single intranasal administration
ETH47Drug
Dose level 1; single inhaled administration
ETH47Drug
Dose level 2; single inhaled administration
ETH47Drug
Dose level 3; single inhaled administration
ETH47Drug
Dose level 4; single inhaled administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of treatment-emergent adverse events (TEAEs)Time frame: From treatment until end of study (d 21)
- Number of serious adverse events (SAEs)Time frame: From enrollment until end of study (day 21)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CRO
Merthyr Tydfil, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.